Results 201 to 208 of about 21,372 (208)

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

Journal of Clinical Pharmacology, 2016
Ahmed Hamed Salem, David Chien, Shekman L Wong   +2 more
exaly  

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis

Cancer Chemotherapy and Pharmacology, 2016
Kevin J Freise, Ahmed Hamed Salem, Shekman Wong   +2 more
exaly  

Venetoclax is safe and efficacious in relapsed/refractory AML

Leukemia and Lymphoma, 2020
Ron Ram, Oren Pasvolsky, Ivetta Danylesko   +2 more
exaly  

Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin

Xenobiotica, 2018
Ahmed Hamed Salem, Manoj S Chiney, Bo Tong   +2 more
exaly  

Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway

International Immunopharmacology, 2022
exaly  

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Journal of Clinical Pharmacology, 2017
Ahmed Hamed Salem, Martin Dunbar, Rod A Humerickhouse   +2 more
exaly  

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

AAPS Journal, 2016
Kevin J Freise, Ahmed Hamed Salem, Rod A Humerickhouse   +2 more
exaly  

Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights

British Journal of Haematology
Boaz Nachmias, Arnon Haran, Aaron Schimmer   +2 more
exaly